Pharmaceutical Material Antiulcer Betahistine Dihydrochloride CAS 5579-84-0

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Betahistine Dihydrochloride
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Store in a Well-Closed Container Away From Moistur
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• MOQ: 1kg
• Mf: C25h32f3n3o4
• MW: 495.53
• CAS No: 5579-84-0
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

Pharmaceutical Material Antiulcer Betahistine Dihydrochloride CAS 5579-84-0

Specification of Analysis

Product Name	Betahistine Dihydrochloride
Appearance	White to almost crystalline powder, very hygroscopic
Assay	99.0%~101.0%
pH	2~3
Loss on drying	≤1.0%
Sulphated ash	≤0.1%
Identification	IR: Similar to the reference standard HPLC: Similar to the reference standard
Residual solvents(2-p-ropanol)	≤0.5%
Solubility	Very soluble in water Freely soluble in alcohol (96%) Practically insoluble in 2-p-ropanol
Clarity of solution	(0.1g in10ml carbon dioxide free water)-clear
2-(2-Hydroxyethyl) p-yridine	≤0.2%
2-Vinylp-yridine	≤0.2%
N-Methyl-N,N-bis(2-Pyridin-2-yl-ethyl)amine	≤0.2%
Other individual impurity	≤0.1%
Total impurities	≤0.5%

What is Betahistine dihydrochloride?

Betahistine dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug. Target: Histamine Receptor Betahistine dihydrochloride, a structural analogue of histamine with weak histamine H(1) receptor agonist and more potent H(3) receptor antagonist properties. Betahistine dihydrochloride acts centrally by enhancing histamine synthesis within tuberomammillary nuclei of the posterior hypothalamus and histamine release within vestibular nuclei through antagonism of H(3) autoreceptors [1]. Therapeutic effects of betahistine in vestibular disorders result from its antagonist properties at histamine H(3) receptors (H(3)Rs). On inhibition of cAMP formation and [(3)H]arachidonic acid release, betahistine behaved as a nanomolar inverse agonist and a micromolar agonist. After acute oral administration, Betahistine increased t-MeHA levels with an ED(50) of 2 mg/kg, a rightward shift probably caused by almost complete first-pass metabolism. Therapeutic effects of betahistine result from an enhancement of histamine neuron activity induced by inverse agonism at H(3) autoreceptors [2].

Fuction and Application of Betahistine dihydrochloride

1.Betahistine (16 mg, twice a day for 3 months continuously) can significantly improve the frequency, intensity and duration of vertigo and its complications, as well as the quality of life of patients with meniere's disease. 
2.Betahistine - dihydrochloride (16 mg each time, three times a day or 48 mg), longer duration of use, two doses can be reduced the number of meniere's disease patient monthly .

Application

1. Applied in food field;
2. Applied in health food field;
3. Applied in pharmaceutical field.